# Anticancer Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anticancer-bioscience

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.anticancerbio.com
- Total disclosed funding: $11M
- Latest round: Angel (Jan 4, 2026)
- Investors on record: 2

## About

Based in Chengdu, China and founded in 2016, Chengdu Anticancer Bioscience Co., Ltd., trading as Anticancer Bioscience, is a precision oncology drugs company that focuses on applying synthetic lethal approaches to develop targeted cancer therapies. It was named as a finalist for the Scrip Awards in the category of China Biopharma Leadership in 2022. Dun Yang, the founder, President and CEO of the company, used to work in the laboratory of Nobel Laureate J. Michael Bishop, M.D. The company has branch offices in St Andrews, San Francisco, Sydney, and Hyderabad. In January 2026, Anticancer Bioscience closed Angel funding from new investor CY Capital.
The company's main product category is anti-cancer drugs. The Company has technology platforms such as chemical compound library, small molecule libraries, natural product libraries, and other technology platforms, which are used for precision lethal oncology drug discovery and development of cancer therapies. The products have served cancer patients.
The company generates revenue by doing R&D, and providing new anti-cancer drugs and cancer therapies.
The Angel funding raised in January 2026 will be used to accelerate technology development and pipeline advancement, further exploring new pathways for cancer treatment.

## Funding rounds

- Angel, Jan 4, 2026 — CY Capital
- Seed, Oct 14, 2021, $11M — 3 Rivers Capital

## Investors

- 3 Rivers Capital (https://capitalatlas.ai/funds/3-rivers-capital) — Seed
- CY Capital (https://capitalatlas.ai/funds/cy-capital) — Angel